Accelerating antiviral drug discovery: lessons from COVID-19
2023 · Nature Reviews Drug Discovery · 174 citations
https://doi.org/10.1038/s41573-023-00692-8
A
Annette von Delft
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
32
Papers
1.2K
Citations
15
h-index
18
i10-index
Annette von Delft is an academic researcher from University of Oxford. The author has contributed to research in topics: Hepatitis C virus research & vaccines and immunoinformatics approaches & HIV Research and Treatment. The author has an h-index of 15, co-authored 28 publications.
ORCID: 0000-0002-7699-8140Papers by this author
worksOpen science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
2023 · Science · 163 citations
https://doi.org/10.1126/science.abo7201
A white-knuckle ride of open COVID drug discovery
2021 · Nature · 44 citations
https://doi.org/10.1038/d41586-021-01571-1
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes
2017 · Vaccine · 38 citations
https://doi.org/10.1016/j.vaccine.2017.10.079
Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors
2025 · Nature Communications · 6 citations
https://doi.org/10.1038/s41467-025-63602-z
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses
2021 · Cell Reports · 4 citations
https://doi.org/10.1016/j.celrep.2021.109103
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat